tiprankstipranks
Trending News
More News >
Can-Fite BioPharma (CANF)
:CANF

Can-Fite BioPharma (CANF) AI Stock Analysis

Compare
576 Followers

Top Page

CA

Can-Fite BioPharma

(NYSE MKT:CANF)

Rating:42Neutral
Price Target:
$1.00
▼(-9.91%Downside)
Can-Fite BioPharma's overall stock score reflects significant financial challenges and a bearish technical outlook. The company's negative profitability, declining revenues, and reliance on external financing are major concerns. Technical indicators suggest caution, while valuation metrics indicate ongoing losses, affecting investor confidence.

Can-Fite BioPharma (CANF) vs. SPDR S&P 500 ETF (SPY)

Can-Fite BioPharma Business Overview & Revenue Model

Company DescriptionCan-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company based in Israel, focused on the development of small molecule therapeutics for the treatment of autoimmune inflammatory diseases, oncology, and liver health. The company leverages its proprietary platform technology to develop its pipeline of drug candidates, which includes Piclidenoson, Namodenoson, and CF602, targeting conditions such as psoriasis, rheumatoid arthritis, liver cancer, and erectile dysfunction.
How the Company Makes MoneyCan-Fite BioPharma generates revenue primarily through licensing agreements and collaborations with pharmaceutical companies for the development and commercialization of its drug candidates. These agreements often include upfront payments, milestone payments based on the achievement of clinical, regulatory, and sales milestones, as well as royalties from product sales. The company also seeks to secure funding through public and private offerings of its securities to support its research and development activities. Significant partnerships and collaborations with other pharmaceutical companies and research institutions are key contributors to its earnings.

Can-Fite BioPharma Financial Statement Overview

Summary
Can-Fite BioPharma is facing significant financial challenges with declining revenues, persistent losses, and reliance on external financing. The income statement shows negative profitability margins and decreasing equity, while the cash flow statement indicates consistent negative free cash flow. Improvements in operational efficiency and revenue growth are crucial to strengthening the company's financial position.
Income Statement
35
Negative
Can-Fite BioPharma's income statement reveals significant challenges, with consistent negative EBIT and net income over the years, indicating ongoing operational inefficiencies. The company has experienced declining revenue, with a revenue decrease of approximately 9.3% from 2023 to 2024. Margins are negative, with a net profit margin of -1169% in 2024, highlighting profitability issues. Despite these challenges, the gross profit margin remains positive due to relatively low cost of goods sold.
Balance Sheet
45
Neutral
The balance sheet shows a mixed picture. Can-Fite BioPharma maintains a low level of debt, with a debt-to-equity ratio of 0.019 in 2024, suggesting limited leverage risk. However, the stockholder's equity has been decreasing, indicating potential erosion in financial stability. The equity ratio stands at 59.6%, reflecting a moderate reliance on equity to finance assets. The decreasing equity may pose future risks if the trend continues.
Cash Flow
40
Negative
Cash flow analysis indicates consistent negative free cash flow, which is a concern for sustainability. However, the free cash flow has improved by 9.5% from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating that operations are not generating sufficient cash to cover net losses. The company has relied on financing activities to sustain operations, as seen with substantial financing cash flow in recent years.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
674.00K743.00K810.00K853.00K763.00K
Gross Profit
674.00K743.00K810.00K853.00K763.00K
EBIT
-8.13M-8.20M-10.10M-12.84M-14.14M
EBITDA
-8.12M-8.18M-10.08M-12.83M-14.13M
Net Income Common Stockholders
-7.88M-7.63M-10.53M-12.60M-14.81M
Balance SheetCash, Cash Equivalents and Short-Term Investments
7.89M8.92M7.98M19.14M8.34M
Total Assets
9.12M9.99M9.28M20.25M9.52M
Total Debt
104.00K40.00K62.00K124.00K67.00K
Net Debt
-4.72M-4.24M-2.92M-4.27M-8.20M
Total Liabilities
3.68M3.75M4.81M5.87M3.45M
Stockholders Equity
5.44M6.24M4.47M14.38M6.07M
Cash FlowFree Cash Flow
-7.64M-8.44M-10.81M-9.87M-12.09M
Operating Cash Flow
-7.64M-8.44M-10.80M-9.86M-12.06M
Investing Cash Flow
1.50M498.00K9.50M-14.51M-26.00K
Financing Cash Flow
6.71M9.14M0.0020.46M17.68M

Can-Fite BioPharma Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.11
Price Trends
50DMA
1.19
Negative
100DMA
1.39
Negative
200DMA
1.72
Negative
Market Momentum
MACD
-0.02
Negative
RSI
49.59
Neutral
STOCH
73.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANF, the sentiment is Neutral. The current price of 1.11 is above the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.19, and below the 200-day MA of 1.72, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 49.59 is Neutral, neither overbought nor oversold. The STOCH value of 73.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CANF.

Can-Fite BioPharma Risk Analysis

Can-Fite BioPharma disclosed 68 risk factors in its most recent earnings report. Can-Fite BioPharma reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023

Can-Fite BioPharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
48
Neutral
$16.96M650.59-24.89%10081.34%
47
Neutral
$18.51M-358.06%95.52%
42
Neutral
$15.62M-122.28%
EQEQ
42
Neutral
$13.57M-88.32%-19.76%-13.20%
35
Underperform
$12.85M-58.78%-126.54%
UBUBX
31
Underperform
$11.72M-231.27%35.08%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CANF
Can-Fite BioPharma
1.11
-1.65
-59.78%
LPCN
Lipocine
3.37
-4.45
-56.91%
EDSA
Edesa Biotech
1.96
-2.49
-55.96%
UBX
Unity Biotechnology
0.70
-0.93
-57.06%
EQ
Equillium
0.38
-0.35
-47.95%
CING
Cingulate Inc
4.54
-3.98
-46.71%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.